Welcome to our dedicated page for RTRX news (Ticker: RTRX), a resource for investors and traders seeking the latest updates and insights on RTRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RTRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RTRX's position in the market.
Retrophin, Inc. (Nasdaq: RTRX) announced on September 10, 2020, the granting of inducement stock options for 38,250 shares and restricted stock units (RSUs) for 7,475 shares to new employees. The stock options have an exercise price of $18.46 per share, vesting over four years. The RSUs also vest over four years, with 25% vesting each year. This initiative is part of Retrophin's strategy to attract talent to support its focus on developing therapies for rare diseases, including its late-stage candidate sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
Retrophin (NASDAQ: RTRX) is participating in two virtual investor conferences in August 2020. The William Blair Biotech Focus Conference will occur on August 6 at 3:00 p.m. ET, followed by the Canaccord Genuity 40th Annual Growth Conference on August 12 at 2:00 p.m. ET. Live webcasts and archived replays will be available for up to 30 days on their website.
Retrophin specializes in therapies for rare diseases, focusing on late-stage development of sparsentan for conditions like FSGS and IgAN, with ongoing research in other rare disorders.
Retrophin, Inc. (NASDAQ: RTRX) reported Q2 2020 net product sales of $48.4 million, an 8% increase from $44.7 million in Q2 2019. Cash and equivalents reached $457.4 million after a $109 million stock offering. The Phase 3 PROTECT study for sparsentan in IgA nephropathy achieved enrollment ahead of schedule, with topline data expected in 2021. R&D expenses decreased to $30.8 million, while SG&A expenses fell to $35.0 million. Despite a net loss of $26.1 million, down from $38.7 million a year prior, the company remains focused on advancing its clinical programs during the ongoing COVID-19 pandemic.
Retrophin (NASDAQ: RTRX) will report its second quarter 2020 financial results on July 30, 2020, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results along with a business update. Interested parties can participate via dial-in numbers or through a live webcast. The call replay will be available from July 30 to August 6, 2020. The company specializes in developing therapies for rare diseases, with a focus on its late-stage product candidate, sparsentan, targeting conditions such as FSGS and IgAN.
Retrophin, Inc. (NASDAQ: RTRX) announced that CEO Eric Dube will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 a.m. ET. A live webcast will be available, with an archived replay accessible for 30 days afterward. Retrophin specializes in developing therapies for rare diseases, with its pipeline featuring sparsentan, which is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). The company also collaborates on additional rare disease research and supports its R&D through revenue from existing commercial products.
Retrophin, Inc. (Nasdaq: RTRX) has announced a public offering of 6,500,000 shares of its common stock priced at $15.50 per share, set to generate approximately $100.8 million in gross proceeds before expenses. The offering is expected to close on June 11, 2020. Additionally, underwriters have a 30-day option for an extra 975,000 shares at the same price. The stocks are registered under a shelf registration statement effective since September 4, 2018. Jefferies, Barclays, and BofA Securities are serving as joint book-running managers.
Retrophin, Inc. (Nasdaq: RTRX) announced its intention to conduct an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The exact terms and size of the offering remain uncertain. Jefferies, Barclays, and BofA Securities are serving as joint book-running managers for this offering. Shares will be offered under a shelf registration statement effective since September 4, 2018. A preliminary prospectus will be filed with the SEC.
Retrophin, a biopharmaceutical firm, announced that its CEO, Eric Dube, Ph.D., will present at the Jefferies 2020 Virtual Healthcare Conference on June 3, 2020, at 2:30 p.m. ET. A live webcast will be available, with an archived replay accessible for 30 days.
The company focuses on developing therapies for rare diseases, particularly sparsentan for FSGS and IgAN. Retrophin is also conducting research on other rare conditions like NGLY1 deficiency and Alagille syndrome, supported by revenues from its commercial products such as Chenodal®, Cholbam®, and Thiola®.
Retrophin reported first quarter 2020 financial results, achieving net product sales of $47.8 million, up from $39.6 million in 2019, primarily driven by increased demand linked to the COVID-19 pandemic. Enrollment in the pivotal DUPLEX Study of sparsentan for FSGS has reached 190 patients, setting the stage for interim efficacy analysis. Research and development expenses decreased to $30.2 million, and a $19 million income tax benefit was recorded due to the CARES Act. Retrophin remains focused on supporting patients amidst the pandemic.
